ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Red Orbit (Free subscription) | yesterday
MOUNTAIN VIEW, Calif., Dec.
Crohn's Disease
5Vote!
3Vote!
Meanwhile, Tea Party On, Suckers!
Bad Attitudes (Free subscription) | 12/05/2009
Ripley has a terrific post up at Whiskey Fire . Read it all here . Teaser follows: …Of course, living in Smalltown, USA means kids and families will experience those things that kids and families everywhere experience as children grow up - skinned knees, stubbed toes, stomach cancer, Crohn's disease, leukemia, brain tumors, massive skin grafting after a fire... you know, those boo-boos that define...
Videos
5Vote!
Unsatisfied gamer sues Activision Blizzard
Video Game Law Blog (Free subscription) | 12/02/2009
Erik Estavillo, the same man who has previously sued Sony Computer Entertainment America (SCEA), Microsoft and Nintendo, has allegedly filed another lawsuit in the Civil Division of the Superior Court of California. This latest suit was filed against Activision Blizzard over the game World of Warcraft. According to Gamerant.com, Mr. Estavillo sued SCEA after he was banned from the Playstation Network...
4Vote!
North Houston woman continues her fight against Crohn's disease
Houston Chronicle (Free subscription) | 11/30/2009
Kierra Lee, a former North Houston resident and now a Texas A&M freshman, does not let Crohn's disease keep her down. Crohn's disease is a debilitating, chronic gastrointestinal illness where the immune system attacks healthy cells in the GI tract. Lee has been successfully managing her disease, and became the 2009 valedictorian of her class at Yates High School, 3703 Sampson.
3Vote!
IBD: Sargramostim for corticosteroid-dependent Crohn's disease
Nature Publishing Group (Free subscription) | 11/30/2009
IBD: Sargramostim for corticosteroid-dependent Crohn's disease Nature Reviews Gastroenterology & Hepatology 6, 689 (2009). doi:10.1038/nrgastro.2009.192 Author: Natalie J. Wood
3Vote!
Pathway Analysis of GWAS Provides New Insights into Genetic Susceptibility to 3 Inflammatory Diseases
PLoS ONE (Free subscription) | 11/30/2009
Although the introduction of genome-wide association studies (GWAS) have greatly increased the number of genes associated with common diseases, only a small proportion of the predicted genetic contribution has so far been elucidated. Studying the cumulative variation of polymorphisms in multiple genes acting in functional pathways may provide a complementary approach to the more common single SNP association...
4Vote!
My body & soul: Anastacia
The Observer (Free subscription) | 11/29/2009
Anastacia, 41, singer Ever spent a night in hospital? This article is probably too short to cover the number of nights I've spent in hospital. I was diagnosed with Crohn's disease at 13 and then I had breast cancer at 29. Hospitals don't scare me, which is good, because I never know when I'm going to have to go in. But I feel comfortable if my mum's there. Do you worry about your weight? At the beginning...
3Vote!
Being philosophical
I.E. Lester (Free subscription) | 11/26/2009
Last weekend I got food poisoning. Or maybe I have a new as yet unidentified allergy. I am allergic to bananas, fennel and alcohol amongst other things so it wouldn't surprise me to learn of another one. All I know is I had a very pleasant meal last Sunday, three course plus mince pies, and by the evening I was starting to feel a bit dodgy. Middle of the night this turned into pretty serious discomfort....
3Vote!
ChemoCentryx Reports Positive PROTECT-1 Study Results For Traficet-EN(TM) At The GASTRO 2009 UEGW/WCOG Conference
Medical News Today (Free subscription) | 11/26/2009
ChemoCentryx, Inc., announced that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile.
4Vote!
Happy Birthday World of Warcraft!
UNOFFICIAL THREESPEECH : 100% Unofficial Sony... (Free subscription) | 11/26/2009
Erik Estavillo is suing Activision Blizzard over World of Warcraft. Erik Estavillo is also a funny guy. That or he's crazy. It could go either way. Estavillo claims the company "continues to maintain a harmful virtual environment to many of its customers by forcing them to follow [World of Warcraft's] sneaky and deceitful practices". And what could those "sneaky and deceitful practices"...
4Vote!
Crazy Professional Plantiff Suing Blizzard Now, Subpoenas Winona Ryder
GayGamer.net (Free subscription) | 11/25/2009
Erik Estavillo is a name I'm sure will be responsible for much future amusement. Originally gaining notoriety for suing Sony after being banned from PSN due to improper conduct, he set his sights next on Nintento and Microsoft -- in the former case, he bricked his Wii while modding it to pirate games illegally (no, seriously) , and in the latter his Xbox 360 suffered from the common "red ring...
5Vote!
Given Imaging: Three Studies Find PillCam(R) SB Enables Earlier Diagnosis and Treatment of GI Diseases Including Crohn's
Market Wire (Free subscription) | 11/25/2009
LONDON (MARKET WIRE) Given Imaging Ltd. (NASDAQ: GIVN), the global leader in patient-friendly GI diagnostic and monitoring solutions, today announced that three new studies demonstrate that PillCam(R) SB endoscopy has a clear impact on how physicians manage GI patients, including those patients suspected of having Crohn's disease. The studies were presented at the Gastro 2009 conference taking place...
4Vote!
ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
The Earth Times Online Newspaper (Free subscription) | 11/25/2009
MOUNTAIN VIEW, Calif., Nov. 25 /PRNewswire/ -- ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderat...
6Vote!
ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
Red Orbit (Free subscription) | 11/25/2009
ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The study demonstrated evidence of clinical efficacy in the reduction...
3Vote!
Winona Ryder, Depeche Mode Factor in WOW Lawsuit
GamePolitics.com (Free subscription) | 11/24/2009
World of Warcraft maker Activision Blizzard is the latest target of a lawsuit by serial suer ( or professional plaintiff ) Erik Estavillo. Filed this morning in the Civil Division of the Superior Court of California, County of Santa Clara, the civil complaint charges Activision Blizzard with “deceitful” business practices, as it “continues to maintain a harmful virtual environment...
The 3 latest articles published by users on Crohn's Disease :
3Vote!
Disease and Therapy Review: Crohn's Disease
aarkstore | 10/22/2009
The Crohn's Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, and an overview of treatments, including 5-ASA, corticosteroids, antibiotics, immune modifiers, biologic therapies, surgery, and other options. Dosing information is provided major products. General information is provided on the size of the Crohn's treatment market. Additional...
3Vote!
Disease and Therapy Review: Crohn's Disease
aarkstore | 10/21/2009
The Crohn's Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, and an overview of treatments, including 5-ASA, corticosteroids, antibiotics, immune modifiers, biologic therapies, surgery, and other options. Dosing information is provided major products. General information is provided on the size of the Crohn's treatment market. Disease...
4Vote!
Autoimmune Market Forecast to 2014
aarkstore | 09/04/2009
If your company is looking to build or vitalize presence in the competitive autoimmune market, you’ll need a tool to give you unshakeable confidence in your decision-making. Autoimmune Market Forecast to 2014 is your all-in-one, comprehensive resource for the most current data available on autoimmune products, drug classes and manufacturers. Expert analysis will help you identify and capitalize on...